Biovista’s Unusual Brand of In Silico Drug Discovery

May 14, 2009Biovista Articles

Interview of Aris Persidis to Bio-IT World’s John Russell May 14, 2009 | It’s interesting what crops up in company executive profiles. Aris Persidis is an accomplished bio-entrepreneur and the co-founder of Biovista along with his brother Andreas Persidis. Aris’s company profile includes the usual details—Cellzome co-founder, Ph.D. from Cambridge University in biochemistry, etc.—but the very last … Read More

The future of drug repositioning

May 1, 2009Biovista Articles

Andreas Persidis of Biovista talks to NGP about the transformational potential of drug repositioning. NGP. Drug repositioning seems to be attracting increasing interest in the pharmaceutical world. Is there a real need for it? Andreas Persidis. Drug repositioning has been attracting the interest of pharmaceutical and biotech companies for two reasons: commercial and scientific. On … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis

April 2, 2009Press Releases

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More